Stephens resumed coverage of Cryoport (CYRX) with an Overweight rating and $13 price target The firm says the company has a large platform of supply chain solutions for the growing cell and gene therapy industry. Cryoport will benefit as the macro environment normalizes and therapies move through the clinical pipeline, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: